Patents by Inventor Nicholas Chiorazzi
Nicholas Chiorazzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9745364Abstract: This invention provides an anti-idiotype antibody that binds to the antigen-binding region of an antibody encoded by antibody genes selected from the group consisting of Set I, Set II, Set III, Set IV, Set V, Set VIa, Set VIb, Set VIc, Set VId, Set VIe, Set VII, and Set VIII, hybridomas and methods of treatments using such.Type: GrantFiled: January 20, 2012Date of Patent: August 29, 2017Assignee: The Feinstein Institute for Medical ResearchInventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Patent number: 9683265Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: GrantFiled: June 29, 2016Date of Patent: June 20, 2017Assignee: The Feinstein Institute for Medical ResearchInventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
-
Publication number: 20160304973Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: ApplicationFiled: June 29, 2016Publication date: October 20, 2016Applicant: The Feinstein Institute For Medical ResearchInventors: Nicholas Chiorazzi, Rajendra N. Darnle, Tarun Wasil
-
Publication number: 20120141462Abstract: This invention provides an anti-idiotype antibody that binds to the antigen-binding region of an antibody encoded by antibody genes selected from the group consisting of Set I, Set II, Set III, Set IV, Set V, Set VIa, Set VIb, Set VIc, Set VId, Set VIe, Set VII, and Set VIII, hybridomas and methods of treatments using such.Type: ApplicationFiled: January 20, 2012Publication date: June 7, 2012Inventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Publication number: 20120128586Abstract: The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic lymphocytic leukemia in the subject. The present invention also provides a method for treating a subject having chronic lymphocytic leukemia comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the “resting re-entry compartment” to treat chronic lymphocytic leukemia in the subject.Type: ApplicationFiled: June 24, 2010Publication date: May 24, 2012Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventors: Carlo Calissano, Nicholas Chiorazzi, Rajendra N. Damle, Piers Patten
-
Patent number: 8119340Abstract: Provided are isolated and purified preparations of a combination of a light chain antibody gene and a heavy chain antibody gene, where the light chain and heavy chain antibody genes are the same among more than one patient with B cell chronic lymphocytic leukemia (B-CLL). Vectors comprising those genes and cells comprising those vectors are also provided, as are isolated and purified antibodies encoded by the antibody genes. Anti-idiotype antibodies, peptides, and aptamers that bind to the antigen-binding region of an antibody encoded by the antibody genes are additionally provided, as are multimeric molecules comprising multiple binding sites that bind to the antigen-binding region of an antibody encoded by the antibody genes.Type: GrantFiled: October 8, 2004Date of Patent: February 21, 2012Assignee: The Feinstein Institute for Medical ResearchInventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Publication number: 20110117555Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: ApplicationFiled: November 19, 2010Publication date: May 19, 2011Inventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
-
Patent number: 7842461Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: GrantFiled: April 26, 2007Date of Patent: November 30, 2010Assignee: The Feinstein Institute for Medical ResearchInventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
-
Publication number: 20090117095Abstract: Provided are isolated and purified preparations of a combination of a light chain antibody gene and a heavy chain antibody gene, where the light chain and heavy chain antibody genes are the same among more than one patient with B cell chronic lymphocytic leukemia (B-CLL). Vectors comprising those genes and cells comprising those vectors are also provided, as are isolated and purified antibodies encoded by the antibody genes. Anti-idiotype antibodies, peptides, and aptamers that bind to the antigen-binding region of an antibody encoded by the antibody genes are additionally provided, as are multimeric molecules comprising multiple binding sites that bind to the antigen-binding region of an antibody encoded by the antibody genes.Type: ApplicationFiled: October 8, 2004Publication date: May 7, 2009Inventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Patent number: 7316906Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: GrantFiled: August 2, 2002Date of Patent: January 8, 2008Assignee: The Feinstein Institute for Medical ResearchInventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
-
Publication number: 20070202534Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: ApplicationFiled: April 26, 2007Publication date: August 30, 2007Inventors: Nicholas Chiorazzi, Rajendra Damle, Tarun Wasil
-
Publication number: 20030082593Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: ApplicationFiled: August 2, 2002Publication date: May 1, 2003Inventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
-
Patent number: 6506551Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: GrantFiled: October 8, 1999Date of Patent: January 14, 2003Assignee: North Shore - Long Island Jewish Research InstituteInventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil